|
Wednesday 12th May 2021 |
Text too small? |
A commercial agreement between Rua Bioscience and Medbloom Limited to supply raw biomass has been concluded by mutual understanding. Rua is now focused on progressing existing discussions with alternative grower partners to supplement the company's existing cultivation facility in Ruatorea.
The conclusion of this agreement will not delay Rua's first export revenue.
In October 2020, Medbloom (a subsidiary of Blooming Hill Flowers) signed a commercial agreement to grow and supply Rua with cannabis plant material - with production expected to begin in 2022. The agreement was contingent upon Medbloom securing adequate capital to expand its operation.
Though disappointed, Rua CEO Rob Mitchell says Rua is well-placed to fill the gap.
Rua is in advanced discussions with a number of other grower partners already producing biomass, with strong horticultural experience and the capability to deliver the volumes needed. There is significant scope for partnership opportunity in the evolving New Zealand industry. Rua understands Medsafe has issued 27 commercial licences under the medicinal cannabis scheme. Other growers will provide the geographical diversification originally offered by Medbloom, safeguarding Rua from potential environmental and other external factors that may affect production.
Please see the link below for details
Rua concludes Medbloom agreement, developing new opportunities
Source: Rua Bioscience Limited
No comments yet
RYM - Ryman Healthcare appoints new independent director
ikeGPS 4Q FY26 and Full Year FY26 Performance Update
HGH - Heartland trading update
CVT - Comvita Rights Offer Opens
GNE - FY26 Q3 Performance Report and Updated Guidance
April 23rd Morning Report
Devon Funds Morning Note - 22 April 2026
AGL - Accordant Group Limited announces opening of Rights Offer
April 22nd Morning Report
BPG - Q4 FY26 Update: ARR reaches $26.8m